Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
about
The role of microRNAs in bladder cancermicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentClinical and pathological implications of miRNA in bladder cancerMiRNAs and miRNA Polymorphisms Modify Drug ResponseIdentification of Personalized Chemoresistance Genes in Subtypes of Basal-Like Breast Cancer Based on Functional Differences Using Pathway AnalysisRecursive Random Lasso (RRLasso) for Identifying Anti-Cancer Drug TargetsThe down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells.The potential of microRNAs in personalized medicine against cancers.MicroRNA-99a and 100 mediated upregulation of FOXA1 in bladder cancer.Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and SurvivinmiR-199a-5p suppresses human bladder cancer cell metastasis by targeting CCR7.Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA.Long non‑coding RNA‑GAS5 acts as a tumor suppressor in bladder transitional cell carcinoma via regulation of chemokine (C‑C motif) ligand 1 expressionPhotodynamic killing of cancer cells by a Platinum(II) complex with cyclometallating ligand.Repression of the miR-93-enhanced sensitivity of bladder carcinoma to chemotherapy involves the regulation of LASS2.Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.Regulation of multidrug resistance by microRNAs in anti-cancer therapyGenomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.MicroRNA in intervertebral disc degeneration.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.Identification and Characterization of Cadmium-Related Genes in Liver Carcinoma.Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell LinesPrognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?MiR-375/SLC7A11 axis regulates oral squamous cell carcinoma proliferation and invasion.Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.Stimulation of the hypoxia pathway modulates chemotherapy resistance in Hodgkin's lymphoma cells.Noncoding RNAs in Therapeutic Resistance of Cancer.A small molecule that induces reactive oxygen species via cellular glutathione depletion.Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis.MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural MesotheliomaGenomic profiling of collecting duct renal carcinomaModulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer.Inhibition of miR-27a suppresses the inflammatory response via the p38/MAPK pathway in intervertebral disc cells.Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.Identification of hub miRNA biomarkers for bladder cancer by weighted gene coexpression network analysis.MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
P2860
Q26744149-BA398E08-0059-489B-8CF0-3C9F69A09A3AQ26778918-CC47E332-F3A1-4FCF-882B-53139576C92DQ27004262-960F3B07-9118-4C39-85C8-A596790723F6Q28079075-E57E071F-6B40-4F8A-A1B2-674272B10870Q28545978-3F421BC3-C0A8-4F44-8C41-D607C6FEAE17Q28550739-C5C2EC8C-3FAA-44EB-901B-9BC9C81EACCCQ33812772-C248F806-044F-4C3E-AFAB-3C8D42670980Q34177547-3A98D4EA-C43F-4A20-B780-6EA82E2E8DC3Q34227727-4E78A7C3-7F6E-4454-B4E5-699CBEF281D9Q34459766-EBEBF1D0-E3AA-4A87-A363-E9759B8CD721Q35832262-B6DB045C-99C8-4BB8-9822-C554B354D086Q35850227-F94F57CB-4035-49A1-B9B1-D6993B654DF1Q36183239-A9DDC6C0-0001-4FB1-84F9-BCDE6148811BQ36379634-C2C116A4-2719-4F57-8FAA-C92D058C18DBQ36390300-1F9F50C9-9BB3-438E-ABD7-886B6C4EB9B0Q36651264-193E69F2-E95A-4678-A7FF-B3AE18004850Q36766823-EAE78486-0255-401E-9196-D15B492E14E4Q37327370-5FE86A7B-20A9-49C6-AEED-F18C2B506893Q37364111-1F3B096E-E9FD-42D6-ACB2-97B6E6EAFD58Q37587311-5FA2BA0D-D80E-4A6C-AE31-BA4E68BF9B2BQ37718224-CB70CFDB-A4CB-4466-9773-4FFE88C72BFEQ38367405-DDE666ED-D54F-46EB-BF80-D2C16CEC22A2Q38633144-B45AFB90-BD7E-4E01-871A-F80C038520E9Q38645044-84A86C6D-6087-4DEA-AB8A-0CE30579216DQ38647100-10F83705-C8D2-429B-8A86-E96E5FCCBB58Q38667456-A1939529-7DBB-46BD-BC51-87F8B1CB6AEBQ38699922-A14E4462-2E61-4260-8D04-8601A33B8478Q38761348-6E3B7906-46CB-45E7-A156-FB4053A63974Q38807893-FF83462B-FA27-4C0A-B607-D637B706D37CQ38885495-F1F4D581-68D7-4C26-AE36-CC36FAE46B30Q38976630-0C6921A7-CE41-458F-B8CF-39ECF7FC837BQ39432577-3EB4F6C9-C8CF-4A41-B01B-58329946FCB8Q39440371-0637C607-92C6-4993-8524-2F1E0F102DF8Q41191000-9036AC3B-E5DB-4F88-9C02-BB8EC454AD69Q42082505-7687233F-6FA6-4096-A3B3-292CC24F230EQ42215256-5B3D94A3-560C-43E0-A02A-6ECFE4DDE01CQ42675891-6CE84C7B-27FA-46AC-923C-9E3B813BAD2FQ46569075-B06BBE7B-D50F-4A44-AE0E-92BE94BF1E9EQ47099037-2C7D61D8-16B4-4C00-85C5-4DDA78410C27Q47890192-0CDA98D8-7E62-422A-876B-A307264D214F
P2860
Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@en
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@nl
type
label
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@en
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@nl
prefLabel
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@en
Reduced expression of miRNA-27 ...... e/glutamate exchanger SLC7A11.
@nl
P2093
P2860
P1476
Reduced expression of miRNA-27 ...... ne/glutamate exchanger SLC7A11
@en
P2093
Arndt Hartmann
Ewa Dudziec
Helen E Bryant
Ross M Drayton
Simone Bertz
Stefan Peter
P2860
P304
P356
10.1158/1078-0432.CCR-13-2805
P407
P50
P577
2014-02-10T00:00:00Z